All In Biotech

NDA 022006 · Lundbeck Pharms LLC

Sabril

Vigabatrin · Oral · Anti-epileptic Agent

Priority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2009

Aug 21, 2009

Approved uses

4

Original approval plus efficacy supplements

Registered trials

28

6 Phase 3, 2 recruiting

FAERS reports

13,897

9,744 serious, 1,337 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: PERMANENT VISION LOSS SABRIL can cause permanent bilateral concentric visual field constriction, including tunnel vision that can result in disability . In some cases, SABRIL also can damage the central retina and may decrease visual acuity [see Warnings and Precautions ( 5.1 )]. The onset of vision loss from SABRIL is unpredictable, and can occur within weeks of starting treatment or sooner, or at any time after starting treatment, even after months or years. Symptoms of vision loss from SABRIL are unlikely to be recognized by patients or caregivers before vision loss is severe. Vision loss of milder severity, while often unrecognized by the patient or caregiver, can still adversely affect function. The risk of vision loss increases with increasing dose and cumulative exposure, but there is no dose or exposure known to be free of risk of vision loss. Vision assessment is...

What it is approved for

From the label in effect Oct 20, 2021.

SABRIL is indicated for the treatment of: Refractory Complex Partial Seizures as adjunctive therapy in patients 2 years of age and older who have responded inadequately to several alternative treatments; SABRIL is not indicated as a first line agent ( 1.1 ) Infantile Spasms - monotherapy in infants 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss ( 1.2 ) 1.1 Refractory Complex Partial Seizures (CPS) SABRIL is indicated as adjunctive therapy for adults and pediatric patients 2 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss [see Warnings and Precautions ( 5.1 )] . SABRIL is not indicated as a first line agent for complex partial seizures. 1.2 Infantile Spasms (IS) SABRIL is indicated as monotherapy for pediatric patients with infantile spasms 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss [see Warnings and Precautions ( 5.1 ) ].

Mechanism: The precise mechanism of vigabatrin’s anti-seizure effect is unknown, but it is believed to be the result of its action as an irreversible inhibitor of γ-aminobutyric acid transaminase (GABA-T), the enzyme responsible for the metabolism of the inhibitory neurotransmitter GABA. This action results in increased levels of GABA in the central nervous system. No direct correlation between plasma concentration and efficacy has been established. The duration of drug effect is presumed to be dependent on the rate of enzyme re-synthesis rather than on the rate of elimination of the drug from the...

Therapeutic areas: Neurology · Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 24, 2020 Supplement 23 · Efficacy OrphanLetterLabel
  • Oct 26, 2013 Supplement 13 · Efficacy · priority review LetterLabel
  • Oct 26, 2013 Supplement 12 · Efficacy · priority review OrphanLabelLetter
  • Aug 21, 2009 Original approval · Type 3 - New Dosage Form · priority review OrphanReviewOtherSummary Review
1 products under this application
  • SABRIL · VIGABATRIN 500MG/PACKET · FOR SOLUTION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Vigabatrin" as an intervention, any sponsor and status, largest first.

All 28 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure2,541
  • drug ineffective1,368
  • drug dose omission990
  • death842
  • pneumonia521
  • somnolence508
  • drug withdrawal convulsions482
  • off label use443
  • vomiting414
  • hospitalisation369
  • product dose omission issue366
  • epilepsy302

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200419
200523
200628
200718
200865
200939
2010275
2011219
2012280
2013211
20141,266
20151,569
20161,483
20171,220
2018959
2019785
2020736
2021786
2022887
20231,001
2024910
2025672
2026446

Recalls

1 FDA enforcement reports for this application.

  • Aug 17, 2023 · Class III · Completed

    Cross contamination with other products

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sabril (Vigabatrin)

2024 spending

$15.2M

Beneficiaries

41

342 claims

Per beneficiary

$370,617

$197.64 per unit

View as table
YearSpending
2020$19,348,728
2021$18,658,682
2022$20,044,400
2023$18,489,554
2024$15,195,305

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 261 on PubMed
  • Epilepsy.

    Marson AG, Maguire M, Ramaratnam S · BMJ Clin Evid 2009 · Systematic Review

  • Epilepsy (partial).

    Maguire M, Marson AG, Ramaratnam S · BMJ Clin Evid 2011 · Systematic Review

  • Epilepsy (partial).

    Maguire M, Marson AG, Ramaratnam S · BMJ Clin Evid 2010 · Systematic Review

  • Vigabatrin.

    Reynolds EH · BMJ 1990 · Clinical Trial, Review

  • Vigabatrin.

    Michelucci R, Tassinari CA · Epilepsy Res Suppl 1991 · Clinical Trial, Randomized Controlled Trial

  • Anticonvulsants for cocaine dependence.

    Minozzi S, Cinquini M, Amato L, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't

Sponsor: Lundbeck Pharms LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.